Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
Asymptomatic Monoclonal Gammopathy of Undermined Significance can cause symptoms. Hyperviscosity syndrome, the problems it causes and possible therapies… One of the most difficult aspects about an
Continue readingPre-Myeloma- Single Bone Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Defined- Symptoms, Causes, Diagnostics- Pre-myeloma is a diagnostic
Continue reading“Nonhematologic grade 3 adverse events occurred in 21 smoldering multiple myeloma patients (38.9%) and included thromboembolism, rash, and lung infection, with no grade 4 events.” Yes, chemotherapy
Continue readingHi David- I was recently diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It was found by labs done because of pins and needles in my arms and legs after a Covid vaccine. Several
Continue readingMGUS patients are more likely to develop more severe PN during treatment with certain drugs used to treat MM (e.g. bortezomib and thalidomide) Hi David- I was diagnosed with Monoclonal Gammopathy
Continue reading“New studies (pre-habilitation) suggest that a multimodal approach that incorporates both physical and psychological prehabilitation interventions may be more effective than a unimodal approach that
Continue readingShould we treat patients with myeloma with multidrug, multitransplant combinations with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality
Continue reading“Lenalidomide (Revlimid) induced a 72% reduction in the risk of progression to symptomatic disease in patients with smoldering multiple myeloma at 3 years” The challenge with pre-myeloma, Monoclonal
Continue reading“Patients with monoclonal gammopathy of undetermined significance (MGUS) have twice the risk of developing multiple myeloma (MM) if they have non-antibody (Ab)-mediated rheumatic diseases (RDs)…” Rheumatic
Continue reading“Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement…in multiple myeloma or MGUS patients?” You’ve been diagnosed with multiple myeloma
Continue reading“…among the lenalidomide-treated patients, grade 3 or 4 hematologic and nonhematologic adverse events occurred in 36 patients (41%), with nonhematologic adverse events occurring in 25 patients
Continue reading“What determines the risk of progression from asymptomatic to symptomatic myeloma…Most widespread and validated adversely predictive chromosomal aberrations (high-risk aberrations) in this
Continue reading